SCHEMBL30833273

SCHEMBL30833273

Cc1cc2c(cc1-c1ccccc1F)C(=O)NCC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 12/20 0.51
▸ PARP11 Q9NR21 8/20 0.51
▸ PARP1 P09874 7/20 0.51
▸ PDPK1 O15530 1/20 0.51
▸ GRM5 P41594 6/20 0.51
▸ PLK4 O00444 1/20 0.44
▸ MAPK13 O15264 1/20 0.44
▸ DAPK3 O43293 1/20 0.44
▸ DYRK3 O43781 1/20 0.44
▸ RPS6KA4 O75676 1/20 0.44
▸ PRKD3 O94806 1/20 0.44
▸ MAP4K4 O95819 1/20 0.44
▸ CHEK2 O96017 1/20 0.44
▸ EGFR P00533 1/20 0.44
▸ CDK1 P06493 1/20 0.44
▸ MET P08581 1/20 0.44
▸ PIM1 P11309 1/20 0.44
▸ RPS6KB1 P23443 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ AXL P30530 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18554703 1.00 PARP10 (0.51) PARP10PARP11PARP1PDPK1GRM5
SCHEMBL12559528 0.77 GRM5 (0.59) PARP10PARP11PARP1PDPK1GRM5
SCHEMBL8155829 0.77 PARP11 (0.68) PARP10PARP11PARP1PDPK1GRM5
SCHEMBL9214155 0.77 PARP10 (0.62) PARP10PARP11PARP1PDPK1GRM5
SCHEMBL18554692 0.75 PARP10 (0.47) PARP10PARP11PARP1PDPK1GRM5
SCHEMBL30833272 0.74 CD274 (0.48) —
SCHEMBL18554736 0.74 CD274 (0.48) —
SCHEMBL18554689 0.74 PARP10 (0.56) PARP10PARP11PARP1PDPK1GRM5
SCHEMBL30833271 0.74 PARP10 (0.56) PARP10PARP11PARP1PDPK1GRM5
SCHEMBL15466514 0.73 PARP10 (0.62) PARP10PARP11PARP1PDPK1GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11945782-B2 Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity SRX CARDIO, LLC (US) 2024-04-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11945782-B2 Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity LDLR, PCSK9, CETP PARP10 2748/4885PARP11 2703/4885PARP1 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback